NOT-CA-22-108: Notice of Correction to PAR-22-216, NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

Notice of Correction to PAR-22-216, NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

Notice Number:

NOT-CA-22-108

Key Dates

Release Date:

July 21, 2022

Related Announcements

PAR-22-216 - NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to delete the mention of a Letter of Intent requirement for PAR-22-216, NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional).

The following section of PAR-22-216 has been corrected:

Part 1. Overview Information, Key Dates

Currently reads:

Letter of Intent Due Date(s): 30 days prior to the application due date

Corrected to read (in bold italics):

Letter of Intent Due Date(s): Not Applicable

All other aspects of PAR-22-216 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Morgan O'Hayre, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7482
Email: [email protected]

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]